EUVIMEDEUVIMED entdecken
Crossref

18 F-FDG Versus Tissue Factor-Targeted PET/CT in Longitudinal Evaluation of the Formation of DEN-Induced Rat Hepatocellular Carcinoma

Buchuan Zhang, Shuqi Zhang, Pei Wang, Dongdong Wang, Shuang Song, Pengtao You, Xiaohua Zhu iD, Bo Yu iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c01010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Buchuan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tissue factor (TF) has emerged as a promising target for the diagnosis and treatment of hepatocellular carcinoma (HCC). However, there is limited data available on TF-related PET imaging for longitudinal monitoring of the pathophysiological changes during HCC formation. Herein, we aimed to explore the TF-expression feature and compare a novel TF-targeted PET probe with 18F-FDG through longitudinal imaging in diethylnitrosamine (DEN)-induced rat HCC. Wistar rats were randomly allocated to three groups receiving DEN: intragastric administration (10 mg/kg, i.g.); intragastric administration (80 mg/kg, i.g.); intraperitoneal administration (80 mg/kg, i.p.) for 12 consecutive weeks. Longitudinal Al18F-NOTA-tTF and 18F-FDG (∼3.7 MBq) PET/CT were performed at weeks 7, 15, and 21. Terminal histopathological evaluation included hematoxylin-eosin staining and immunohistochemical analysis of Ki-67, AFP, and TF expression. In DEN-induced HCC rats (80 mg/kg, i.p. and i.g.), longitudinal 18F-FDG PET/CT revealed temporal metabolic progression, with no detectable lesions at week 7 but distinct hypermetabolic foci appearing by week 15 (4 lesions/group) and increasing to 12 lesions/group at week 21. Quantitative analysis demonstrated significant SUVmax increases in both models from weeks 15 to 21 (i.p.: 1.53 ± 0.54 to 1.87 ± 0.53; i.g.: 1.34 ± 0.37 to 1.77 ± 1.08), though notable heterogeneity emerged with 33.3% of i.p. lesions showing paradoxical SUVmax reduction. In contrast, the Al18F-NOTA-tTF demonstrated superior early detection, identifying lesions as early as week 7 (2 lesions/group) with progressive detection rates reaching 5 lesions by week 15 and 21 (i.p.)/12 (i.g.) lesions at week 21. From weeks 15 to 21, the Al18F-NOTA-tTF exhibited consistently increasing SUVmax (i.p.: 0.56 ± 0.23 to 0.76 ± 0.30; i.g.: 0.47 ± 0.13 to 0.58 ± 0.13), with sustained uptake in 90% (i.p.) and 83% (i.g.) of lesions. Immunohistochemistry demonstrated overexpression of Ki-67, AFP, and TF in PET-positive regions. The longitudinal 18F-FDG PET imaging exhibits significant spatial, temporal, and quantitative heterogeneity in detecting lesions during hepatocarcinogenesis, while TF-targeted PET imaging shows superior capabilities in early and advanced HCC detection. This complementary information highlights the complexity of hepatocarcinogenesis and supports the potential clinical translation of TF-targeted PET for improved HCC detection and characterization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFluorodeoxyglucose F18Carcinoma, HepatocellularLiver NeoplasmsAnimalsRatsRats, WistarDiethylnitrosamineMaleRadiopharmaceuticals

Stichwörter der Autor:innen

18F-FDGdiethylnitrosamine (DEN)hepatocarcinogenesislongitudinal imagingtissue factor

Substanzen

Fluorodeoxyglucose F18DiethylnitrosamineRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
  • Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan 4…
  • Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan 430065, China.

ORCID-Profile: Xiaohua Zhu, Bo Yu

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine

Zitieren

APA

Zhang, B., Zhang, S., Wang, P., Wang, D., Song, S., You, P., Zhu, X., & Yu, B. (2025). 18 F-FDG Versus Tissue Factor-Targeted PET/CT in Longitudinal Evaluation of the Formation of DEN-Induced Rat Hepatocellular Carcinoma. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01010

Vancouver

Zhang B, Zhang S, Wang P, Wang D, Song S, You P, et al. 18 F-FDG Versus Tissue Factor-Targeted PET/CT in Longitudinal Evaluation of the Formation of DEN-Induced Rat Hepatocellular Carcinoma. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c01010

BibTeX
@article{Zhang2025,
  author = {Zhang, Buchuan and Zhang, Shuqi and Wang, Pei and Wang, Dongdong and Song, Shuang and You, Pengtao and Zhu, Xiaohua and Yu, Bo},
  title = {18 F-FDG Versus Tissue Factor-Targeted PET/CT in Longitudinal Evaluation of the Formation of DEN-Induced Rat Hepatocellular Carcinoma},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c01010}
}
Kostenlos starten →